Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

Total product revenues increased ... interested in the progress of Amgen’s GLP-1 receptor candidate, MariTide (maridebart cafraglutide), for obesity. Top-line 52-week data from the phase II ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

In the second quarter, Amgen's product net sales climbed by 20% year ... one of the fastest-growing categories of medicine. A top-line data readout is expected this year with the company already ...

Amgen’s third-quarter product sales grew 24% (or 8% excluding ... Management raised its top-line guidance for 2024 by $100 million at the midpoint to $33 billion-$33.8 billion and narrowed ...

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...